Evercore on Sarepta (SRPT) Post Stat News Article: 'probably sets up for the adcomm briefing documents and tone to be somewhat more negative'
Tweet Send to a Friend
Evercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $149.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
